There is provided an isolated antibody that binds to the extracellular domain of PDGFR² and neutralizes PDGFR² activity, said antibody comprising a V L domain comprising CDRs LCDR1, LCDR2, and LCDR3 and a V H domain comprising CDRs HCDR1, HCDR2, and HCDR3, wherein: LCDR1 has the amino acid sequence shown in SEQ ID NO: 433, optionally the amino acid sequence shown in SEQ ID NO: 443； LCDR2 has the amino acid sequence shown in SEQ ID NO: 434； LCDR3 has the amino acid sequence shown in SEQ ID NO: 435, optionally the amino acid sequence shown in SEQ ID NO: 444； HCDR1 has the amino acid sequence shown in SEQ ID NO: 436, optionally the amino acid sequence shown in SEQ ID NO: 445； HCDR2 has the amino acid sequence shown in SEQ ID NO: 437； HCDR3 has an amino acid sequence selected from the group consisting of SEQ ID NOs: 438-442
